Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
605 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,821 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02470910 | Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04190667 | Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer | unknown | — | 1,300 | Lei LiOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00214058 |
| Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer |
| completed |
| Phase 2 |
| 36 |
| University of Wisconsin, MadisonOTHER |
| 1 |
| Nov 19, 2019 |
| clinicaltrials |
| NCT00445887 | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer | completed | Phase 2 | 60 | Gynecologic Oncology GroupNETWORK | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02096783 | Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer | completed | N/A | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03373058 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery(EHTASEOCCS) | unknown | Phase 3 | 310 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03220932 | Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer(HIPOVA-01) | unknown | Phase 3 | 132 | Hospices Civils de LyonOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT01753908 | Broccoli Sprout Extract in Treating Patients With Breast Cancer | completed | Early Phase 1 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03754569 | Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer(MicroPCI) | completed | N/A | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04101760 | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer | unknown | Phase 3 | 200 | Lei LiOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT01856543 | Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation | completed | Phase 3 | 143 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 297 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02376231 | To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study(PJEOC) | completed | N/A | 120 | Dr Thumuluru Kavitha MadhuriOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03302884 | Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma(CIDOC) | unknown | N/A | 150 | Institut Paoli-CalmettesOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT02578888 | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | completed | N/A | 95 | Albert Einstein College of MedicineOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT01815476 | The Prone Breast Radiation Therapy Trial | completed | N/A | 378 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03247478 | Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure(CTREP) | completed | — | 160 | Peking UniversityOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01737151 | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer | terminated | N/A | 19 | Virginia Commonwealth UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | recruiting | Phase 3 | 360 | Japanese Gynecologic Oncology GroupOTHER | 2 | Aug 30, 2019 | clinicaltrials |
| NCT01504126 | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT03523299 | Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer | withdrawn | N/A | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 21, 2019 | clinicaltrials |
| NCT03077659 | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | completed | Phase 2 | 16 | NanOlogy, LLCINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01682772 | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer(TOPARP) | unknown | Phase 2 | 148 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT02520115 | Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | completed | Phase 1 | 50 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT01196429 | Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 3 | Aug 8, 2019 | clinicaltrials |
| NCT03451812 | Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer(PCAPETMR) | unknown | — | 120 | Chang Gung Memorial HospitalOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00513695 | Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | completed | Phase 2 | 68 | University of WashingtonOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04001023 | Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia(OVANOX) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01747798 | Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 10 | Mayo ClinicOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT00023712 | Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00041080 | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 139 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01028885 | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00022659 | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025155 | Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00053365 | Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00113373 | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00429793 | Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT04031378 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | unknown | Phase 2 | 100 | Fundacao ChampalimaudOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00093626 | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00132067 | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00993616 | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Dec 11, 2019source: clinicaltrials